Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

EGF 105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (T) based systemic therapy and cranial radiotherapy (RT)

EGF 105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (T) based systemic therapy and cranial radiotherapy (RT). J Clin Oncol. 2007; 25(18S):abstract 1012.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.